AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Feb 4, 2025
32559_dirs_2025-02-03_81db464b-9353-476d-aeaf-c08f5b471afc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-01-30
Reporting Person: Jung Melita Sun (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-30 | Common Stock | P | 2250.00 | $5.11 | Acquired | 2250.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-30 | Stock Option (Right to Buy) | $4.64 | A | 325000.00 | Acquired | 2035-01-29 | Common Stock (325000.00) | Direct |
Footnotes
F1: Includes 2,250 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024.
F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.